CASI Pharmaceuticals (CASI) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free CASI Stock Alerts $3.69 +0.14 (+3.94%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 1:07 PM | finance.yahoo.comCASI Pharmaceuticals, Inc. (CASI)May 23, 2024 | americanbankingnews.comCASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.comMay 15, 2024 | prnewswire.comCASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)May 14, 2024 | finanznachrichten.deCASI Pharmaceuticals, Inc.: Casi Pharmaceuticals Announces First Quarter 2024 Business And Financial ResultsMay 14, 2024 | investorplace.comCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | prnewswire.comCASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSApril 24, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From CASI Pharmaceuticals, Inc. (NASDAQ:CASI)April 24, 2024 | finance.yahoo.comBioInvent International AB: Interim Report January-March 2024April 10, 2024 | investing.comCASI Pharmaceuticals updates on Juventas disputeApril 8, 2024 | finance.yahoo.comCASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASMarch 28, 2024 | benzinga.comRecap: CASI Pharmaceuticals Q4 EarningsMarch 28, 2024 | markets.businessinsider.comCASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 28, 2024 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSMarch 18, 2024 | finanznachrichten.deAptevo Therapeutics: Aptevo Participating in The Springtime Partnering Event, a Bio-Europe ConferenceMarch 16, 2024 | finance.yahoo.comCASI Apr 2024 2.500 callMarch 11, 2024 | markets.businessinsider.comPsyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic DivisionMarch 8, 2024 | msn.comAptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare moversMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 10.000 callMarch 7, 2024 | finance.yahoo.comCASI Mar 2024 7.500 putMarch 5, 2024 | marketbeat.comTrading was temporarily halted for "CASI" at 03:03 PM with a stated reason of "LULD pause."March 5, 2024 | msn.comCASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese PatientsMarch 5, 2024 | marketbeat.comTrading was temporarily halted for "CASI" at 09:03 AM with a stated reason of "LULD pause."March 5, 2024 | msn.comCASI stock rises on positive interim data from early stage trial for its NHL treatment in ChinaMarch 5, 2024 | marketwatch.comCASI Pharma Shares Soar After Positive Preliminary Trial Data for Cancer ImmunotherapyMarch 5, 2024 | prnewswire.comCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaFebruary 20, 2024 | msn.comCASI begins dosing lymphoma patients with pralatrexate in ChinaFebruary 18, 2024 | msn.comCASI Pharmaceuticals Reveals Business and Financial Updates Quarter 2024February 17, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.39CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above Two Hundred Day Moving Average of $4.39February 16, 2024 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINAFebruary 16, 2024 | prnewswire.comCASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINAFebruary 13, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CymaBay Therapeutics (CBAY), G1 Therapeutics (GTHX) and Gritstone Oncology (GRTS)February 9, 2024 | marketbeat.comCASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above Two Hundred Day Moving Average of $4.24CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.24January 31, 2024 | es-us.finanzas.yahoo.comEnhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific OfficerJanuary 3, 2024 | finance.yahoo.comSwitch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology OfficerDecember 28, 2023 | benzinga.comCASI Pharmaceuticals Stock (NASDAQ:CASI) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comCASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Price Is Right But Growth Is Lacking After Shares Rocket 33%December 16, 2023 | morningstar.comCASI Pharmaceuticals Inc CASINovember 15, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To KnowNovember 14, 2023 | markets.businessinsider.comCASI Pharmaceuticals Posts Narrower Loss In Q3November 14, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$0.35, revenue of $8.84MNovember 14, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNovember 8, 2023 | markets.businessinsider.comCASI : Juventas' CNCT 19 Approved In China For R/R B-cell Acute Lymphoblastic Leukemia TreatmentAugust 14, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for CASI Pharmaceuticals (CASI)August 11, 2023 | markets.businessinsider.comCASI Pharmaceuticals, Inc. Q2 Loss WidensAugust 11, 2023 | msn.comCASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82MAugust 11, 2023 | finance.yahoo.comCASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESAugust 10, 2023 | msn.comIonis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)August 10, 2023 | msn.comProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue EstimatesAugust 1, 2023 | finance.yahoo.comMundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsJuly 20, 2023 | finance.yahoo.comCleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here CASI Media Mentions By Week CASI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CASI News Sentiment▼0.550.85▲Average Medical News Sentiment CASI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CASI Articles This Week▼51▲CASI Articles Average Week Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Capricor Therapeutics News Today Puma Biotechnology News Today Omeros News Today Zevra Therapeutics News Today Inventiva News Today Telomir Pharmaceuticals News Today Organigram News Today Incannex Healthcare News Today Trevi Therapeutics News Today Atossa Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CASI) was last updated on 5/29/2024 by MarketBeat.com Staff From Our Partners4 Cryptos BETTER than BitcoinTrue Market InsidersWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyHow Biden has already won 2024Porter & CompanyNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss Ratings41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
